¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"suicide inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® suicide ÇÑ±Û ÀÚ»ì
¼³¸í   
  ½º½º·Î ÀÚ½ÅÀÇ ¸ñ¼ûÀ» ²÷À½. Áï, ÇàÀ§ÀÚ°¡ ÀÚ½ÅÀÇ Á×À½À» ÃÊ·¡ÇÒ Àǵµ¸¦ °¡Áö°í ÀÚ½ÅÀÇ »ý¸íÀ» ²÷´Â ÇàÀ§. ÀÚ»ìÀÇ ¿µ¾î´ëÀÀ¾îÀΠsuicideÀÇ ¾î¿øÀº ¶óƾ¾îÀÇ sui(ÀÚ±â ÀÚ½ÅÀ»)¿Í caedo(Á×ÀÌ´Ù)ÀÇ µÎ ³¹¸»ÀÇ ÇÕ¼º¾îÀÌ´Ù. ¿©±â¼­ ¾Ë ¼ö ÀÖµíÀÌ, ÀÚ»ìÀ̶õ ±× ¿øÀÎÀÌ °³ÀÎÀûÀ̵砻çȸÀûÀ̵ç, ´ç»çÀÚ°¡ ÀÚÀ¯Àǻ翡 ÀÇÇÏ¿© ÀÚ½ÅÀÇ ¸ñ¼ûÀ» ²÷´Â ÇàÀ§¸¦ ¸»ÇÑ´Ù. ÀÌ Á¤ÀǴ Àϰߠ¸í¹éÇϱâ´Â Çϳª ½ÇÁ¦·Î´Â ¿©·¯ ¹®Á¦°¡ ÀÖ´Ù. ÀÚ»ìÀÇ ¿øÀÎÀº º¹ÀâÇÏ°í ÆÄ¾ÇÇϱ⠾î·Á¿îµ¥, Åë°è¿¡ ÀÇÇϸ頽Űæ¼è¾à-½Ç¿¬-º´°í-»ýȰ°í-°¡Á¤ºÒÈ­-Àå·¡¿¡ ´ëÇÑ °í¹Î-»ç¾÷½ÇÆÐ-¿°¼¼ µî ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±× Áß¿¡¼­µµ ¿°¼¼-º´°í-½Å°æ¼è¾à-½Ç¿¬-°¡Á¤ºÒÈ­°¡ µÎµå·¯Áö°Ô ¸¹´Ù. À̰ÍÀ» ³²³àº°·Î º¸¸é ³²ÀÚ¿¡°Ô´Â ½Å°æ¼è¾à°ú º´°í°¡ ¸¹°í, ¿©ÀÚ¿¡°Ô´Â °¡Á¤ºÒÈ­¿Í ½Ç¿¬ÀÌ ¸¹´Ù. ±×¸®°í ¿¬·Éº°·Î´Â Ã»¼Ò³â¿¡¼­´Â ½Ç¿¬°ú ¿°¼¼°¡ ¸¹°í, ³ëÀο¡¼­´Â º´°í°¡ Æ¯Â¡ÀûÀ¸·Î ¸¹´Ù. °¡Á¤ºÒÈ­´Â 20~30´ë¿¡ ¸¹´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • assisted suicide
    º¸Á¶ÀÚ»ì
  • suicide
    ÀÚ»ì
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • angiotensin converting enzyme inhibitor
    ¾ØÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    1. ¾ïÁ¦Á¦ 2. ¾ïÁ¦ÀÎÀÚ
  • mitotic inhibitor
    À¯»çºÐ¿­¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • suicide
    ÀÚ»ì
  • inhibitor
    ¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • double suicide
    ÀÌÁßÀÚ»ì
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • involuntary suicide
    ºÒ¼öÀÇÀÚ»ì
  • suicide
    ÀÚ»ì
  • silent suicide
    Ä¡·á°ÅºÎÀÚ»ì
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • clotting inhibitor
    ÀÀ°í¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • CAI=£¾carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à, ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú.
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • RIMA, see reversible inhibitor of MAO-A
    °¡¿ªÀû ´Ü°¡¾Æ¹Î-A »êÈ­È¿¼Ò¾ïÁ¦Á¦
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor
    ¾ïÁ¦ÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • attempted suicide
    ÀÚ»ì¹Ì¼ö(í»ß¯Ú±âÄ)
  • automatic suicide
    ÀÚµ¿Àû ÀÚ»ì
  • double suicide
    ÀÌÁßÀÚ»ì
  • involuntary suicide
    ºÒ¼öÀÇÀÚ»ì
  • silent suicide
    Ä¡·á°ÅºÎÀÚ»ì
  • suicide
    ÀÚ»ì(í»ß¯)
  • suicide genes
    ÀÚ»ì À¯ÀüÀÚ
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • beta (¥â)-lactamase inhibitor
    º£Å¸¶ôŸ¸¶Á¦¾ïÁ¦Á¦
  • c inhibitor deficiency
    º¸Ã¼ ÀúÁöÀÎÀÚ °áÇÌÁõ(ÜÍô÷îÁò­ì×í­ÌÀù¹ñø)
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀú ÇØ¹°Áú, ź»êÅ»¼ö¾ïÁ¦¾à.
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à(¡­ðæúªå·), ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • 32P suicide
    32P ÀÚ¸ê(í»Øþ)
  • radioactive suicide
    ¹æ»ç¼º ÀÚ¸ê(Û¯ÞÒàõí»Øþ)
  • suicide inhibition
    ÀÚ¸ê ÀúÇØ(í»ØþîÁúª)
  • suicide substrate
    ÀÚ¸ê ±âÁú(í»ØþÐñòõ)
  • active site-directed irreversible inhibitor
    Ȱ¼º(üÀàõ)ÀÚ¸®ÁöÇâÀû ºÒ°¡¿ªÀúÇØÁ¦(ò¦ú¾îÜÝÕʦæ½îÁúªð¥)
  • Bowman-Birk inhibitor
    "º¸¿ì¸¸-¹÷Å© ÀúÇØÀÚ(îÁúªí­), º¸¿ì¸¸-¹÷Å© ÀúÇØÁ¦(îÁúªð¥)"
  • competitive inhibitor
    °æÇÕÀúÇØÁ¦(ÌæùêîÁúªð¥)
  • enzyme-inhibitor complex
    È¿¼Ò-ÀúÇØÁ¦ º¹ÇÕü (ý£áÈîÁúªð¥ÜÜùêô÷)
  • heme-controlled inhibitor
    Èû-Á¦¾î(ð¤åÙ) ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor
    ÀúÇØÁ¦(îÁúªð¥)
  • inhibitor constant
    ÀúÇØÁ¦»ó¼ö(îÁúªð¥ßÈâ¦)
  • irreversible inhibitor
    ºñ°¡¿ª ÀúÇØÁ¦(ުʦæ½îÁúªð¥)
  • Kunitz inhibitor
    Äï´ÏÃ÷ ÀúÇØÁ¦(îÁúªð­)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • noncompetitive inhibitor
    ºñ°áÇÕ ÀúÇØÁ¦(ު̿ùêîÁúªðº)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦Á¦, ¾ïÁ¦¹°Áú, ¾ïÁ¦ÀÎÀÚ, ¾ïÁ¦½Å°æ, ¾ïÁ¦À¯ÀüÀÚ, ¾ïÁ¦¾à
  • suicide
    ÀÚ»ì
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
BPTI basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in...
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
MSDI Martin Suicide Depression Inventory
PAS para aminosalicylate; Parent Attitude Scale; patient administration system; patient appointments and...
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PAS Physician assisted suicide
ACE inhibitor angiotensin converting enzyme inhibitor
CPI 1-cysteine proteinase inhibitor
PIC 1-plasmin inhibitor complex
PAI-1 Plaminogen Activator Inhibitor-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigenic suicide
    Ç׿ø¿¡ ÀÇÇÑ ¸²ÇÁ±¸ÀÇ ÀÚ¸ê
    °íµµ·Î ¹æ»ç Ȱ¼ºÀÌ ÀÖ´Â Ç׿øÀ» »ýü¿¡ Åõ¿©Çϸé ÀÌ Ç׿ø¿¡ ´ëÇÏ¿© °¨¼ö¼ºÀÌ ÀÖ´Â ¸²ÇÁ±¸´Â °¨¼Ò ³»Áö ºÒȰ¼ºÈ­µÇ¾î ¹ö¸°´Ù. µû¶ó¼­ ¹æ»ç Ȱ¼ºÀÌ ¾ø´Â °°Àº Ç׿øÀ» Åõ¿©Çصµ ÀÌ Ç׿ø¿¡ ƯÀÌÀûÀÎ ¸é¿ª ÀÀ´äÀº »ý±âÁö ¾Ê°Ô µÈ´Ù. À̰ÍÀº Ç׿ø¿¡ ¹ÝÀÀÇÏ´Â ¸²ÇÁ±¸°¡ ¹æ»ç Ȱ¼ºÀÌ ÀÖ´Â Ç׿øÀ» °áÇÕ½ÃÅ´À¸·Î½á ¹æ»ç´É¿¡ ÀÇÇÑ ¼¼Æ÷ ¼Õ»óÀ» ÀԾ ¾ß±âµÇ´Â °ÍÀÌ´Ù. À̰ÍÀ» Ç׿ø¿¡ ÀÇÇÑ ¸²ÇÁ±¸ÀÇ ÀÚ¸êÀ̶ó°í ÇÑ´Ù.
  • double suicide
    ÀÌÁß ÀÚ»ì
  • suicide
    ÀÚ»ì
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ ÀÀ°í °áÇÕü
  • C1-esterase inhibitor
    C1-esterase ¾ïÁ¦ ¹°Áú
  • cell wall inhibitor
    ¼¼Æ÷ º® ÇÕ¼º ¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°í ÀÎÀÚ ¾ïÁ¦Á¦
  • collagenase inhibitor
    Äݶó°Ô³ªÁ¦ ¾ïÁ¦ ¹°Áú
  • cyclooxygenase inhibitor
    »çÀÌŬ·Î¿Á½ÃÁö³×ÀÌÁî ¾ïÁ¦Àç
  • dopa decarboxylase inhibitor
    µµÆÄ µ¥Ä«¸£º¹½Ç·¹À̽º ¾ïÁ¦ÀÚ
  • lipoxygenase inhibitor
    ¸®ÆÜ½ÃÁö³×À̽º ¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç ÀúÇØÁ¦, ´ë»ç ¾ïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ ±ÝÁöÁ¦
    ÁßÇÕ ¹ÝÀÀÀ» ¹æÇØÇϱ⵵ Çϰí, ÁßÁöÇÒ ¼ö ÀÖ´Â ¹°Áú.
  • virus hemagglutination inhibitor
    ¹ÙÀÌ·¯½º ÀûÇ÷±¸ ÀÀÁý¹ÝÀÀ ¾ïÁ¦ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
suicide The act of killing oneself.
(12 Dec 1998)
suicide, assisted Deliberate acceleration of death of a competent patient with an incurable disease or in the extremes of suffering. The patient seeking assistance in taking his own life may ask the help of a physician or other health professional, a family member, or a friend. The milieu may be a hospital, nursing home, or private residence. Assistance to the person in dire physical or psychological distress may take the form of lethal doses of medications or chemicals to be taken orally or by injection through human intervention or with a so-called suicide machine.
(12 Dec 1998)
suicide, attempted The unsuccessful attempt to kill oneself.
(12 Dec 1998)
suicide substrate A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
a1-trypsin inhibitor A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin.
Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor.
(05 Mar 2000)
ACE inhibitor <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure.
Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes.
Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril.
(12 Mar 1998)
aldose reductase inhibitor <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes.
Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy.
Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes.
(09 Oct 1997)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
aromatase inhibitor Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens.
(05 Mar 2000)
beta-lactamase inhibitor <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance.
(05 Mar 2000)
Bowman-Birk inhibitor A polypeptide that will inhibit both trypsin and chymotrypsin.
(05 Mar 2000)
C1 esterase inhibitor An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema.
(05 Mar 2000)
carbonate dehydratase inhibitor An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues.
See: acetazolamide, dichlorphenamide.
Synonym: carbonic anhydrase inhibitor.
(05 Mar 2000)
carbonic acid inhibitor <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma.
(27 Sep 1997)
carbonic anhydrase inhibitor <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma.
Examples include acetazolamide, dichlorphenamide and methazolamide.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitor
    ¾ïÁ¦ÀÚ(¹°);¹ÝÀÀ¾ïÁ¦Á¦
  • suicide
    ÀÚ»ì
  • double suicide
    Á¤»ç
  • race suicide
    ¹ÎÁ·Àû ÀÚ»ì;¹ÎÁ· ÀÚ¸ê(»ê¾Æ Á¦ÇÑ¿¡ ÀÇÇÑ Àα¸ÀÇ Á¡°¨)
  • suicide
    ÀÚ»ì;ÀÚ¸ê;ÀÚ»ìÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á